ROIVANT SCIENCES LTD

Roivant Sciences insider buys show director confidence: Keith Manchester’s new RSUs and options signal long‑term growth amid market volatility.

Roivant Sciences insider moves: 5,054 RSUs + 10,531 options awarded to directors on 16 Sept 2026, signalling long‑term alignment and a subtle liquidity boost for investors.

Insider selling fuels Roivant’s stock wobble—Melissa Epperly’s latest 4,938‑share sale signals potential market shake‑ups and investor caution.

Gold Daniel Allen’s recent 5,133‑share sell‑off of Roivant Sciences shows disciplined profit‑taking amid a 189% yearly rally, hinting at a gradual portfolio rebalancing while he still holds a sizable stake.

Roivant Sciences insider trades: Oren Ilan sells 2,378 shares at $40.94 – see how routine tax‑settlements and option exercises affect investor confidence.

Insightful analysis of Meghan Fitzgerald’s buy‑low/sell‑high moves at Roivant Sciences, revealing insider confidence and a balanced long‑term strategy for investors.

Insightful look at Roivant’s insider buy‑sell rhythm: how Mayukh Sukhatme’s $3.85 dip buys and $37 sell‑outs reveal short‑term tactics and long‑term confidence.

ROIVANT Sciences insider trade: CEO buys at $3.85, sells at $36.23, capturing $32/share profit while staying net‑neutral—an insight into portfolio tactics, not a sell signal.

Insider buys 17,750 Roivant shares while selling options and shares, signaling confidence in its R&D pipeline and long‑term upside.

Roivant insider sale: Keith Mancaster off‑loads 600,000 shares on June 26, 2026 at $35, dropping only slightly below market. Explore what this signals for investors.